Iron chelators as mitophagy agents: Potential and limitations
Jazyk angličtina Země Francie Médium print-electronic
Typ dokumentu časopisecké články, přehledy
PubMed
39265234
DOI
10.1016/j.biopha.2024.117407
PII: S0753-3322(24)01292-7
Knihovny.cz E-zdroje
- Klíčová slova
- Cancer, Cardiovascular diseases, Iron chelators, Iron heomeostais, Mitophagy, Neurodegenerative diseases,
- MeSH
- chelátory železa * farmakologie terapeutické užití MeSH
- homeostáza účinky léků MeSH
- lidé MeSH
- mitochondrie * metabolismus účinky léků MeSH
- mitofagie * účinky léků MeSH
- železo * metabolismus MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- Názvy látek
- chelátory železa * MeSH
- železo * MeSH
Mitochondrial autophagy (mitophagy) is very important process for the maintenance of cellular homeostasis, functionality and survival. Its dysregulation is associated with high risk and progression numerous serious diseases (e.g., oncological, neurodegenerative and cardiovascular ones). Therefore, targeting mitophagy mechanisms is very hot topic in the biological and medicinal research. The interrelationships between the regulation of mitophagy and iron homeostasis are now becoming apparent. In short, mitochondria are central point for the regulation of iron homeostasis, but change in intracellular cheatable iron level can induce/repress mitophagy. In this review, relationships between iron homeostasis and mitophagy are thoroughly discussed and described. Also, therapeutic applicability of mitophagy chelators in the context of individual diseases is comprehensively and critically evaluated.
Citace poskytuje Crossref.org
